Targeted genotyping of circulating tumor DNA for classical Hodgkin Lymphoma monitoring: a prospective study.

@article{Camus2020TargetedGO,
  title={Targeted genotyping of circulating tumor DNA for classical Hodgkin Lymphoma monitoring: a prospective study.},
  author={Vincent Camus and Mathieu Viennot and Justine Lequesne and Pierre-Julien Viailly and {\'E}lodie Bohers and Lucile Bessi and B{\'e}n{\'e}dicte Marcq and Pascaline Etancelin and Sydney Dubois and Jean-Michel Picquenot and Elena-Liana Veresezan and Marie Cornic and Lucie Burel and Justine Loret and St{\'e}phanie Becker and Pierre Decazes and Pascal Lenain and St{\'e}phane Lepr{\^e}tre and Emilie Lemasle and H{\'e}l{\`e}ne Lanic and Anne-Lise M{\'e}nard and Nathalie Contentin and Herv{\'e} Tilly and Aspasia Stamatoullas and Fabrice Jardin},
  journal={Haematologica},
  year={2020}
}
  • Vincent Camus, Mathieu Viennot, +22 authors Fabrice Jardin
  • Published in Haematologica 2020
  • Medicine
  • The relevance of circulating tumor DNA (ctDNA) analysis as a liquid biopsy and minimal residual disease tool in the management of classical Hodgkin Lymphoma (cHL) patients was demonstrated in retrospective settings and remains to be confirmed in a prospective setting. We developed a targeted Next-Generation sequencing (NGS) panel for fast analysis (AmpliSeq technology) of nine commonly mutated genes in biopies and ctDNA of cHL patients. We then conducted a prospective trial to assess ctDNA… CONTINUE READING

    Create an AI-powered research feed to stay up to date with new papers like this posted to ArXiv